Supporting the

Neuroendocrine Cancer Community

Chemotherapy and Targeted Treatments

Chemotherapy is a cancer treatment where medicine is used to kill cancer cells.

There are many different types of chemotherapy, but they all work in a similar way, to stop cancer cells reproducing, which prevents them from growing and spreading in the body.

Chemotherapy can be given orally (in tablets) or Intravenously (through a vein) to slow tumour growth or try to reduce tumour size:

  • Intravenous chemotherapy is usually done in hospital and involves chemotherapy drugs being given through a tube in a vein in your hand, arm or chest
  • Oral chemotherapy usually involves taking a course of medicine at home, with regular check-ups in hospital.

Chemotherapy is often the 1st line treatment of choice for “poorly differentiated” Neuroendocrine Cancer, that is, Neuroendocrine Carcinomas (NEC) – from any site.

It may also be effective in certain Lung and Pancreatic Neuroendocrine Tumours (NETs) – but less helpful for others, therefore other options for treatment are considered in these patients.

Chemotherapy can be given as a standalone therapy – as a single chemotherapy drug or a combination of chemotherapy drugs – but it may also be used to increase tumour cell sensitivity to radiation therapies or be given before and/or after surgery.

In Neuroendocrine Cancer combination chemotherapy is usually given – combinations that may be used include:

  • Streptozocin and Etoposide
  • Carboplatin or Cisplatin and Etoposide
  • Capecitabine and Temozolamide (CapTem).

Your oncologist (cancer specialist) or nurse specialist will be able to give you both written and verbal information about the chemotherapy drug(s) that will be used in your care – this information will also include any potential side-effects and also any alert signs to look out for that may need urgent medical review. You will also be given contact details for the chemotherapy unit and an on-call 24hr number to ensure you have immediate access to care should you need it.

Targeted Molecular Therapies – can be given orally (in tablets) or Intravenously (through a vein) to slow tumour growth or try to reduce tumour size.

They are drugs or other substances that work against cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer. Many different targeted therapies have been approved for use in cancer treatment. These therapies include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Further information on these different types of therapy can be found at CRUK.

Current Targeted Molecular Therapies that are used in Neuroendocrine Cancers –  treat ‘well-differentiated’ Grade 1-2 Neuroendocrine Tumours (NETs) – and include:

  • Everolimus (Afinitor) – which is a targeted drug that blocks mTOR, a protein in cells that normally helps them grow and divide. Everolimus may also stop tumors from developing new blood vessels, which can help limit their growth.

Everolimus is currently licensed within the UK to treat inoperable non-functioning, well differentiated, Grade 1-2 Neuroendocrine Tumours that start in the pancreas, gastrointestinal system or lung(s) and are showing signs of ongoing growth and / or spread.

  • Sunitinib (Sutent) is a targeted drug that works by stopping tumours from developing new blood vessels (angiogenesis) and also blocking growth-stimulating proteins in the cancer cell itself.

Sunitinib is currently licensed within the UK to treat inoperable non-functioning, well-differentiated, Grade 1-2 Neuroendocrine Tumours that start in the pancreas and is showing signs of ongoing growth and / or spread.

What are the key difference between Chemotherapy and Targeted Molecular Therapies?

Targeted therapies act on specific molecular targets that are associated with cancer, whereas most chemotherapies act on all rapidly dividing normal and cancerous cells.

Targeted therapies often block tumor cell proliferation (cytostasis), and have a specific target whereas chemotherapy kills both tumour and normal rapidly diving cells cells (cytotoxic) and does not have a specific molecular target. 

In Neuroendocrine Cancer – chemotherapy is primarily used to treat Neuroendocrine Carcinoma, whereas the named Targeted Molecular Therapies here, are used only in Neuroendocrine Tumours.

Immunotherapy uses our immune system to fight cancer, by helping the immune system to recognise and attack cancer cells. Some types of immunotherapy are also called targeted treatments or biological therapies. It can be given on its own or alongside  other cancer treatments.

At present the only licensed immunotherapy available in the UK for Neuroendocrine Cancer – is Avelumab – which is used in the treatment of Merkel Cell Carcinoma (Neuroendocrine carcinoma of the Skin) that has spread (metastasised).

Effects of Treatment

Neuroendocrine Cancer Treatments work in a variety of ways – and whilst we wish it wasn’t the case, side-effects can occur – not will occur – but can occur.

Many of these, if they happen, can be mild and manageable – others may cause an alteration or adjustment in treatment, such as reduced dose or interval – occasionally a treatment may have to stop – either temporarily ( a ‘treatment break’)  or permanently, because the side-effect is more severe.

You may also be given treatments in a different order to what was first planned or how you may see them given in others – remember – your treatment plan will be personalised to you.

But it is only possible to deal with changes and side-effects, if you are able to talk them through with your specialist nurse or team.

If you notice a change, or don’t feel well, during or after a treatment – it may be tempting to ignore it or not mention it or wait a few weeks to see if things improve. You may be worried that if you do highlight any changes, your treatment may be stopped. However, the sooner your team knows what is happening, the sooner they can help you to deal with any changes – which will not always mean stopping treatment.

Changes or new symptoms may not always be caused by your treatment – Neuroendocrine Cancer itself can cause alterations in health – and other unrelated health issues can also occur. So, it can be helpful to know what to expect from treatment, what to look out for – and, importantly, when and who to contact if changes occur.

About Us

Neuroendocrine Cancer UK is a UK wide charity solely dedicated to providing support and information to those affected by Neuroendocrine Cancer.


Subscribe to our Newsletter to stay update with our latest news.


Holly House, 74 Upper Holly Walk, Leamington Spa CV32 4JL